Erythropoietin and its carbamylated derivative prevent the development of experimental diabetic autonomic neuropathy in STZ-induced diabetic NOD-SCID mice

Experimental Neurology

Volumn 209, Issue 1, 2008, Pages 161-170

  Schmidt, Robert E ^a   Green, Karen G ^a   Feng, Dongyan ^a   Dorsey, Denise A ^a   Parvin, Curtis A ^a   Lee, Jin Moo ^a   Xiao, Qinlgi ^a   Brines, Michael ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Warren Pharmaceuticals Inc   (United States)

Author keywords

Autonomic neuropathy; Diabetes; Ganglia; Neuroaxonal dystrophy; Neuropathology; Sympathetic; Synapse

Indexed keywords

COMPLEMENTARY DNA; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBAMOYLATION; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE MODEL; DISEASE SEVERITY; DYSTROPHY; HEMATOPOIETIC CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; MOUSE STRAIN; NERVE CELL CULTURE; NEUROPROTECTION; NON OBESE DIABETIC SEVERE COMBINED IMMUNE DEFICIENT MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; SYMPATHETIC NERVE CELL;

ANIMALS; CARBAMATES; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; ERYTHROPOIETIN, RECOMBINANT; GANGLIA, SYMPATHETIC; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED NOD; MICE, SCID; NEURITES; RECEPTORS, ERYTHROPOIETIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 37549024253     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2007.09.018     Document Type: Article

References (67)

1. Ando Y., Asahara K., Obayashi K., Suhr O., Yonemitsu M., Yamashita T., Tashima K., Uchino M., and Ando M. Autonomic dysfunction and anemia in neurologic disorders. J. Auton. Nerv. Syst. 61 (1996) 145-148
2. Beynon G. The influence of the autonomic nervous system in the control of erythropoietin secretion in the hypoxic rat. J. Physiol. 266 (1977) 347-360
3. Biaggioni I., Robertson D., Krantz S., Jones M., and Haile V. The anemia of primary autonomic failure and its reversal with recombinant erythropoietin. Ann. Intern. Med. 121 (1994) 181-186
4. Bianchi R., Buyukakilli B., Brines M., Savino C., Cavaletti G., Oggioni N., Lauria G., Borgna M., Lombardi R., Cimen B., Comelekoglu U., Kanik A., Tataroglu C., Cerami A., and Ghezzi P. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 823-828
5. Bianchi R., Gilardini A., Rodriguez-Menendez V., Oggioni N., Canta A., Colombo T., Michele G.D., Martone S., Sfacteria A., Piedemonte G., Grasso G., Beccaglia P., Ghezzi P., D'Incalci M., Lauria G., and Cavaletti G. Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth. Eur. J. Cancer 43 (2007) 710-717
6. Blunt T., Gell D., Fox M., Taccioli G.E., Lehmann A.R., Jackson S.P., and Jeggo P.A. Identification of a nonsense mutation in the carboxyl-terminal region of DNA-dependent protein kinase catalytic subunit in the scid mouse. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 10285-10290
7. Bosman D.R., Winkler A.S., Marsden J.T., Macdougall I.C., and Watkins P.J. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 24 (2001) 495-499
8. Bosman D.R., Osborne C.A., Marsden J.T., Macdougall I.C., Gardner W.N., and Watkins P.J. Erythropoietin response to hypoxia in patients with diabetic autonomic neuropathy and non-diabetic chronic renal failure. Diabet. Med. 19 (2002) 65-69
9. Brines M.L., and Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat. Rev., Neurosci. 6 (2005) 484-494
10. Brines M.L., Ghezzi P., Keenan S., Agnello D., de Lanerolle N.C., Cerami C., Itri L.M., and Cerami A. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 10526-10531
11. Brines M.L., Grasso G., Fiordaliso F., Sfacteria A., Ghezzi P., Fratelli M., Latini R., Xie Q.-W., Smart J., Su-Rick C.-J., Pobre E., Diaz D., Gomez D., Hand C., Coleman T., and Cerami A. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 14907-14912
12. Cai F., and Helke C.J. Abnormal PI3 kinase/Akt signal pathway in vagal afferent neurons and vagus nerve of streptozotocin-diabetic rats. Brain Res. Mol. Brain Res. 110 (2003) 234-244
13. Campana W.M., Misasi R., and O'Brien J.S. Identification of a neurotrophic sequence in erythropoietin. Int. J. Mol. Med. 1 (1998) 235-241
14. Clark R.G. Recombinant human insulin-like growth factor I (IGF-I): risks and benefits of normalizing blood IGF-I concentrations. Horm. Res. 62 Suppl 1 (2004) 93-100
15. Cotroneo P., Maria Ricerca B., Todaro L., Pitocco D., Manto A., Ruotolo V., Storti S., Damiani P., Caputo S., and Ghirlanda G. Blunted erythropoietin response to anemia in patients with Type 1 diabetes. Diabetes Metab. Res. Rev. 16 (2000) 172-176
16. Craig K.J., Williams J.D., Riley S.G., Smith H., Owens D.R., Worthing D., Cavill I., and Phillips A.O. Anemia and diabetes in the absence of nephropathy. Diabetes Care 28 (2005) 1118-1123
17. Crawford J. Erythropoietin: high profile, high scrutiny. J. Clin. Oncol. 25 (2007) 1021-1023
18. Digicaylioglu M., Garden G., Timberlake S., Fletcher L., and Lipton S.A. Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 9855-9860
19. Drueke T.B., Locatelli F., Clyne N., Eckardt K.U., Macdougall I.C., Tsakiris D., Burger H.U., and Scherhag A. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. 355 (2006) 2071-2084
20. Duchen L.W., Anjorin A., Watkins P.J., and Mackay J.D. Pathology of autonomic neuropathy in diabetes mellitus. Ann. Intern. Med. 92 (1980) 301-303
21. Estus S., Zaks W.J., Freeman R.S., Gruda M., Bravo R., and Johnson Jr. E.M. Altered gene expression in neurons during programmed cell death: identification of c-jun as necessary for neuronal apoptosis. J. Cell Biol. 127 (1994) 1717-1727
22. Ewing D.J., Campbell I.W., and Clarke B.F. The natural history of diabetic autonomic neuropathy. Q. J. Med. 49 (1980) 95-108
23. Fink G.D., and Fisher J.W. Erythropoietin production after renal denervation or beta-adrenergic blockade. Am. J. Physiol. 230 (1976) 508-513
24. Henke M., Mattern D., Pepe M., Bezay C., Weissenberger C., Werner M., and Pajonk F. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?. J. Clin. Oncol. 24 (2006) 4708-4713
25. Hoeldtke R.D., and Streeten D.H. Treatment of orthostatic hypotension with erythropoietin. N. Engl. J. Med. 329 (1993) 611-615
26. Hoke A. Neuroprotection in the peripheral nervous system: rationale for more effective therapies. Arch. Neurol. 63 (2006) 1681-1685
27. Hosking D.J., Bennett T., and Hampton J.R. Diabetic autonomic neuropathy. Diabetes 27 (1978) 1043-1055
28. Huang T.J., Verkhratsky A., and Fernyhough P. Insulin enhances mitochondrial inner membrane potential and increases ATP levels through phosphoinositide 3-kinase in adult sensory neurons. Mol. Cell. Neurosci. 28 (2005) 42-54
29. Kawakami K., Abe H., Harayama N., and Nakashima Y. Successful treatment of severe orthostatic hypotension with erythropoietin. Pacing Clin. Electrophysiol. 26 (2003) 105-107
30. Keswani S.C., Buldanlioglu U., Fischer A., Reed N., Polley M., Liang H., Zhou C., Jack C., Leitz G.J., and Hoke A. A novel endogenous erythropoietin mediated pathway prevents axonal degeneration. Ann. Neurol. 56 (2004) 815-826
31. Keswani S.C., Leitz G.J., and Hoke A. Erythropoietin is neuroprotective in models of HIV sensory neuropathy. Neurosci. Lett. 371 (2004) 102-105
32. Koh S.H., Kim Y., Kim H.Y., Won Cho G., Kim K.S., and Kim S.H. Recombinant human erythropoietin suppresses symptom onset and progression of G93A-SOD1 mouse model of ALS by preventing motor neuron death and inflammation. Eur. J. Neurosci. 25 (2007) 1923-1930
33. Leist M., Ghezzi P., Grasso G., Bianchi R., Villa P., Fratelli M., Savino C., Bianchi M., Nielsen J., Gerwien J., Kallunki P., Larsen A.K., Helboe L., Christensen S., Pedersen L.O., Nielsen M., Torup L., Sager T., Sfacteria A., Erbayraktar S., Erbayraktar Z., Gokmen N., Yilmaz O., Cerami-Hand C., Xie Q.W., Coleman T., Cerami A., and Brines M. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305 (2004) 239-242
34. Lipton S.A. Erythropoietin for neurologic protection and diabetic neuropathy. N. Engl. J. Med. 350 (2004) 2516-2517
35. Masuda S., Chikuma M., and Sasaki R. Insulin-like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes. Brain Res. 746 (1997) 63-70
36. McGill J.B., and Bell D.S. Anemia and the role of erythropoietin in diabetes. J. Diabetes Its Complicat. 20 (2006) 262-272
37. Melli G., Jack C., Lambrinos G.L., Ringkamp M., and Hoke A. Erythropoietin protects sensory axons against paclitaxel-induced distal degeneration. Neurobiol. Dis. 24 (2006) 525-530
38. Montero M., Poulsen F.R., Noraberg J., Kirkeby A., van Beek J., Leist M., and Zimmer J. Comparison of neuroprotective effects of erythropoietin (EPO) and carbamylerythropoietin (CEPO) against ischemia-like oxygen-glucose deprivation (OGD) and NMDA excitotoxicity in mouse hippocampal slice cultures. Exp. Neurol. 204 (2007) 106-117
39. Perera R., Isola L., and Kaufmann H. Effect of recombinant erythropoietin on anemia and orthostatic hypotension in primary autonomic failure. Clin. Auton. Res. 5 (1995) 211-213
40. Rao S.V., and Stamler J.S. Erythropoietin, anemia, and orthostatic hypotension: the evidence mounts. Clin. Auton. Res. 12 (2002) 141-143
41. Recio-Pinto E., Rechler M.M., and Ishii D.N. Effects of insulin, insulin-like growth factor-II, and nerve growth factor on neurite formation and survival in cultured sympathetic and sensory neurons. J. Neurosci. 6 (1986) 1211-1219
42. Ricerca B.M., Todaro L., Caputo S., Cotroneo P., Damiani P., Manto A., Pitocco D., Storti S., and Ghirlanda G. Blunted erythropoietin response to anemia in type 1 diabetic patients. Diabetes Care 22 (1999) 647
43. Roesler R., Quevedo J., and Schroder N. Erythropoietin, glutamate, and neuroprotection. N. Engl. J. Med. 351 (2004) 1465-1466 (author)
44. Rundles R. Diabetic neuropathy. General review with report of 125 cases. Medicine 24 (1945) 111-160
45. Saito T., Tojo K., Nishimura R., Kageyama S., and Tajima N. Coefficient of variation of R-R intervals in electrocardiogram is a sensitive marker of anemia induced by autonomic neuropathy in type 1 diabetes. Diabetes Res. Clin. Pract. 78 (2007) 60-64
46. Sampson M.J., Wilson S., Karagiannis P., Edmonds M., and Watkins P.J. Progression of diabetic autonomic neuropathy over a decade in insulin-dependent diabetics. Q. J. Med. 75 (1990) 635-646
47. Savino C., Pedotti R., Baggi F., Ubiali F., Gallo B., Nava S., Bigini P., Barbera S., Fumagalli E., Mennini T., Vezzani A., Rizzi M., Coleman T., Cerami A., Brines M., Ghezzi P., and Bianchi R. Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. J. Neuroimmunol. 172 (2006) 27-37
48. Schmidt R. Neuropathology and pathogenesis of diabetic autonomic neuropathy. In: Tomlinson D.R. (Ed). Neurobiology of Diabetic Neuropathy (2002), Academic Press, Amsterdam 267-292
49. Schmidt R.E., and Plurad S.B. Ultrastructural and biochemical characterization of autonomic neuropathy in rats with chronic streptozotocin diabetes. J. Neuropathol. Exp. Neurol. 45 (1986) 525-544
50. Schmidt R.E., and Plurad S.B. The effect of pancreatic islet transplantation and insulin therapy on experimental diabetic autonomic neuropathy. Diabetes 32 (1983) 532-540
51. Schmidt R.E., Plurad S.B., Parvin C.A., and Roth K.A. Effect of diabetes and aging on human sympathetic autonomic ganglia. Am. J. Pathol. 143 (1993) 143-153
52. Schmidt R.E., Dorsey D.A., Beaudet L.N., Plurad S.B., Parvin C.A., and Miller M.S. Insulin-like growth factor I reverses experimental diabetic autonomic neuropathy. Am. J. Pathol. 155 (1999) 1651-1660
53. Schmidt R.E., Dorsey D.A., Beaudet L.N., Frederick K.E., Parvin C.A., Plurad S.B., and Levisetti M.G. Non-obese diabetic mice rapidly develop dramatic sympathetic neuritic dystrophy: a new experimental model of diabetic autonomic neuropathy. Am. J. Pathol. 163 (2003) 2077-2091
54. Schmidt R.E., Dorsey D.A., Beaudet L.N., Parvin C.A., Zhang W., and Sima A.A. Experimental rat models of types 1 and 2 diabetes differ in sympathetic neuroaxonal dystrophy. J. Neuropathol. Exp. Neurol. 63 (2004) 450-460
55. Singh A.K., Szczech L., Tang K.L., Barnhart H., Sapp S., Wolfson M., and Reddan D. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 355 (2006) 2085-2098
56. Singhal A., Cheng C., Sun H., and Zochodne D.W. Near nerve local insulin prevents conduction slowing in experimental diabetes. Brain Res. 763 (1997) 209-214
57. Sirén A.-L., Fratelli M., Brines M., Goemans C., Casagrande S., Lewczuk P., Keenan S., Gleiter C., Pasquali C., Capobianco A., Mennini T., Heumann R., Cerami A., Ehrenreich H., and Ghezzi P. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 4044-4049
58. Sowade B., Sowade O., Mocks J., Franke W., and Warnke H. The safety of treatment with recombinant human erythropoietin in clinical use: a review of controlled studies. Int. J. Mol. Med. 1 (1998) 303-314
59. Spallone V., Maiello M.R., Kurukulasuriya N., Barini A., Lovecchio M., Tartaglione R., Mennuni G., and Menzinger G. Does autonomic neuropathy play a role in erythropoietin regulation in non-proteinuric Type 2 diabetic patients?. Diabet. Med. 21 (2004) 1174-1180
60. Spivak J.L. Erythropoietin use and abuse: when physiology and pharmacology collide. Adv. Exp. Med. Biol. 502 (2001) 207-224
61. Steensma D.P., and Loprinzi C.L. Erythropoietin use in cancer patients: a matter of life and death?. J. Clin. Oncol. 23 (2005) 5865-5868
62. Tam J., Diamond J., and Maysinger D. Dual-action peptides: a new strategy in the treatment of diabetes-associated neuropathy. Drug Discov. Today 11 (2006) 254-260
63. Vinik A.I., Maser R.E., Mitchell B.D., and Freeman R. Diabetic autonomic neuropathy. Diabetes Care 26 (2003) 1553-1579
64. Winkler A.S., Marsden J., Chaudhuri K.R., Hambley H., and Watkins P.J. Erythropoietin depletion and anaemia in diabetes mellitus. Diabet. Med. 16 (1999) 813-819
65. Winkler A.S., Landau S., and Watkins P.J. Erythropoietin treatment of postural hypotension in anemic type 1 diabetic patients with autonomic neuropathy: a case study of four patients. Diabetes Care 24 (2001) 1121-1123
66. Winkler A.S., Landau S., Watkins P., and Chaudhuri K.R. Observations on haematological and cardiovascular effects of erythropoietin treatment in multiple system atrophy with sympathetic failure. Clin. Auton. Res. 12 (2002) 203-206
67. Zhang F., Signore A.P., Zhou Z., Wang S., Cao G., and Chen J. Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms. J. Neurosci. Res. 83 (2006) 1241-1251